Analysts expect Agomab Therapeutics NV to report revenue of 452,126.05 for 2026, against a range of 425,073.54 to 479,178.56. The most recent reported year, 2025, came in at 0.00, a 100.0% miss against the 684,665.23 consensus.
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | - | ||
| High Estimate | 746,378.90 | 479,178.56 | 607,842.55 | ||
| Low Estimate | 622,951.56 | 425,073.54 | 508,765.89 | ||
| Consensus Estimate | 684,665.23 | 452,126.05 | 558,304.22 |
Pull Wall Street consensus for Agomab Therapeutics NV (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AGMB&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AGMB", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AGMB&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();